Radzivil T T | AMiner学者主页

全面呈现 [Radzivil T T] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（3）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Баланс Микроэлементов И Показатели Гомеостаза Как Прогностические Критерии При Прогрессировании Рака Пищеварительного Тракта

И. А. Хлусов,А. М. Некрасова,Г. Б. Слепченко, Г К Жерлов,С. А. Коломиец,А. В. Карпович,Т. Т. Радзивил

Interaction between chemical compound of biological substrates (hair, tumor tissue) and laboratory and clinical parameters was determined for detecting progression of gastrointestinal tract cancer. The content of microelements such as zinc, copper, selenium, iron, iodine, mercury, cadmium, lead, arsenic and chromium in hair and epithelial lesions was estimated by the method of inversion voltamperometry. Fifty-four patients with stage I-IV cancer and 20 patients with benign tumors of the stomach, colon and rectum were examined. Mineral compound of papillomas was studied in 14 patients. The control group consisted of 74 healthy subjects. The study results showed that the level of CD95 on blood leukocytes was significantly increasing as the tumor was growing (r = 0,48; p 6+ levels in hair and tumor tissue (r = 0,54; p

2007Siberian Journal of Oncology（2007）

引用

AI阅读

2Efficacy of Supplemental Anti-Inflammatory Therapy with Fenspiride in Chronic Obstructive and Nonobstructive Bronchitis

L. I. Volkova,A. A. Budkova, N. N. Filonova, E. I. Khristolyubova, E. B. Kutuzova, N. V. Koroleva,T. T. Radzivil, Z. R. Aminova,A. G. Chuchalin

Objective: The objective of this randomised, nonblind study was to assess the efficacy of fenspiride as complementary anti-inflammatory therapy in combination with ipratropium bromide in patients with chronic bronchitis (CB). A comparison was made with ipratropium bromide alone, the generally accepted standard therapy for CB.

2005Clinical Drug Investigation（2005）引用：4

引用

AI阅读

3[Efficacy of a Complementary Antiinflammatory Treatment with Erespal in Chronic Obstructive and Nonobstructive Bronchitis].

LI Volkova,AA Budkova, NN Filonova, EL Khristolyubova, EB Kutuzova, NV Koroleva,TT Radzivil, ZR Aminova, AG Chuchalin

AIM:To compare efficacy of atrovent alone and in combination with erespal in patients with chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD).MATERIAL AND METHODS:Of 80 participants of the trial (51 male and 29 female--63.75 and 36.25%, respectively) who had CB or COPD, 39 patients (28 with CB and 11 with COPD) received 6-month combined treatment with erespal (160 mg/day) and atrovent (160 mcg/day) and 41 patients (32 with CB and 9 with COPD) received atrovent monotherapy in the same dosage.RESULTS:Combined therapy produced positive changes in dyspnea, sputum characteristics and its discharge, cough, monotherapy improved sputum discharge and relieved cough; pulmonary ventilation improved in both groups especially in those on monotherapy. CB patients showed low cytosis, percentage and absolute count of neutrophils, absolute count of lymphocytes and eosinophils in induced sputum. In CB patients percentage of lymphocytes reduced while count of macrophages went up. Combined treatment including erespal also promoted a significant fall of serum and sputum TNFalpha and IL-8 reduction in the sputum.CONCLUSION:Erespal+atrovent treatment proved more effective than atrovent alone. It is recommended for both CB and COPD patients without marked disorders of external respiration function.

2004TERAPEVTICHESKII ARKHIV（2004）引用：23

引用

AI阅读